Tag:

Biocon

Latest Headlines

Latest Headlines

Bristol-Myers deepens its ties to Biocon's CRO and Indian R&D

As many drugmakers scale down their R&D presences in India, Bristol-Myers Squibb is strengthening its relationship with Syngene, the CRO arm of local giant Biocon.

Novartis fighting two-pronged legal battle in India on Galvus patent

Novartis, already in a legal battle to try to keep India's Wockhardt from launching a generic of its diabetes blockbuster Galvus, says it is now trying to prevent Biocon from doing the same thing.

UPDATED: Roche legal action messes with Mylan's India launch of its Herceptin biosimilar

Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.

Mylan has hired away a new India president from Biocon, its partner there

Mylan turned to India's Biocon last year for expertise on making biosimilars. This year, the generic drug maker is turning to Biocon for someone to run its extensive operations in that country.

Mylan, Biocon ready to roll out Herceptin biosimilar in India

Mylan said today that it and Indian biologics partner Biocon have nabbed the first approval in India and will have a biosimilar of Herceptin (trastuzumab) ready to roll out early next year.

Biocon: Syngene is Asia's fastest-growing CRO

Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.

India's economic meltdown pushes Biocon to build elsewhere

India, facing its worst economic crisis in two decades, has in recent years invested little in basic infrastructure like power, water and roads. These shortcomings are forcing some of its most successful drugmakers to look outside the country when they need new manufacturing sites.

India's Biocon promises Herceptin biosim launch by year's end

Now that the Swiss drugmaker has decided to forego a patent fight over the breast cancer drug in India, domestic drugmakers are rubbing their hands together in anticipation.

India's Biocon begins marketing psoriasis drug Alzumab

The company is looking for partners to expand commercialization of the therapy around the globe.

Can India's Biocon land a global partner for its new psoriasis drug?

Biocon's Kiran Mazumdar-Shaw has been one of the leaders in India attempting to build a biotech community capable of developing drugs for worldwide markets. Now the company has a test case on its hands.